Orexigen Therapeutics, Inc

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-04-20
Last Posted Date
2016-09-29
Lead Sponsor
Orexigen Therapeutics, Inc
Target Recruit Count
30
Registration Number
NCT02745912

Naltrexone/Bupropion Cardiovascular Outcomes Study

First Posted Date
2015-12-22
Last Posted Date
2017-02-27
Lead Sponsor
Orexigen Therapeutics, Inc
Target Recruit Count
67
Registration Number
NCT02638129

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

First Posted Date
2014-10-08
Last Posted Date
2014-12-11
Lead Sponsor
Orexigen Therapeutics, Inc
Target Recruit Count
80
Registration Number
NCT02259179
Locations
🇺🇸

Quintiles Phase One Services, LLC, Overland Park, Kansas, United States

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

First Posted Date
2013-01-09
Last Posted Date
2015-12-29
Lead Sponsor
Orexigen Therapeutics, Inc
Target Recruit Count
242
Registration Number
NCT01764386
Locations
🇺🇸

Radiant Research-Akron, Akron, Ohio, United States

🇺🇸

PMG Research of Winston-Salem, Hickory, North Carolina, United States

🇺🇸

PMG Research of Salisbury, Salisbury, North Carolina, United States

and more 9 locations

Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder

First Posted Date
2008-09-25
Last Posted Date
2012-11-29
Lead Sponsor
Orexigen Therapeutics, Inc
Target Recruit Count
8
Registration Number
NCT00758966
Locations
🇺🇸

Northbrooke Research Center, Brown Deer, Wisconsin, United States

🇺🇸

Atlanta Center for Medical Research, Atlanta, Georgia, United States

🇺🇸

Indiana University School of Medicine, Indianapolis, Indiana, United States

and more 8 locations

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

First Posted Date
2008-08-14
Last Posted Date
2012-11-29
Lead Sponsor
Orexigen Therapeutics, Inc
Target Recruit Count
26
Registration Number
NCT00734435
Locations
🇺🇸

Florida Clinical Research Center, Maitland, Florida, United States

🇺🇸

UCI Medical Center, Orange, California, United States

🇺🇸

Synergy Research, National City, California, United States

and more 6 locations

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

First Posted Date
2008-07-09
Last Posted Date
2015-01-06
Lead Sponsor
Orexigen Therapeutics, Inc
Target Recruit Count
46
Registration Number
NCT00711477
Locations
🇺🇸

Brookhaven National Laboratory Medical Department, Upton, New York, United States

Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

First Posted Date
2008-07-03
Last Posted Date
2012-11-29
Lead Sponsor
Orexigen Therapeutics, Inc
Target Recruit Count
729
Registration Number
NCT00709371
Locations
🇺🇸

Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

🇺🇸

Welborn Clinic, Evansville, Indiana, United States

🇺🇸

Miami Research Associates, Miami, Florida, United States

and more 17 locations
© Copyright 2024. All Rights Reserved by MedPath